α1-acid glycoprotein (AGP)-induced platelet shape change involves the Rho/Rho kinase signalling pathway

Peter Gunnarsson; Louise Levander; Peter Påhlsson; Magnus Grenegård

doi:10.1160/TH09-03-0156

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 102(04): 694-703
DOI: 10.1160/TH09-03-0156

Platelets and Blood Cells

Schattauer GmbH

α₁-acid glycoprotein (AGP)-induced platelet shape change involves the Rho/Rho kinase signalling pathway

Peter Gunnarsson

¹Division of Drug Research, Linköping University, Linköping, Sweden

,

Louise Levander

²Division of Cell Biology, Linköping University, Linköping, Sweden

,

Peter Påhlsson

²Division of Cell Biology, Linköping University, Linköping, Sweden

,

Magnus Grenegård

¹Division of Drug Research, Linköping University, Linköping, Sweden

› Author Affiliations

Abstract

Summary

α₁-acid glycoprotein (AGP) is an acute-phase protein that contributes to inflammation processes.The role of AGP in platelet activation and thrombosis is, however, largely unknown.Therefore, we thoroughly investigated the effects of AGP on human platelets. Platelets were isolated from healthy volunteers and subsequently exposed to AGP. Platelet responses were monitored as change in light transmission, intracellular calcium concentration, light microscopy and protein phosphorylation by Western blot.We found that AGP induced platelet shape change independently of a second release of adenine nucleotides or thromboxane A₂, and that effect was abolished by endotheliumderived platelet inhibitors such as nitric oxide (NO) and adenosine. Furthermore,AGP triggered a minor calcium response and a pronounced Rho/Rho-kinase-dependent increase in Thr696 phosphorylation of myosin phosphatase target subunit 1 (MYPT1). Moreover, the Rho/Rho-kinase inhibitor Y-27632 significantly decreased the AGP-induced shape change.The results also showed that the AGP-elicited shape change was antagonised by pretreatment with low doses of collagen and thrombospondin-1.Our results describe a novel mechanism by whichAGP stimulates platelet shape change via activation of the Rho/Rhokinase signalling pathway. Physiological important platelet inhibitors, such as NO, completely counterbalance the effect of AGP. Hence, the present study indicates that AGP directly contributes to platelet activation,which in turn might have an impact in physiological haemostasis and/or pathological thrombosis.

Keywords

α₁-acid glycoprotein - platelets - Rho-kinase - shape change

Full Text

References

References
1 Schmid K. Preparation and properties of serum and plasma proteins. XXIX. Separation from human plasma of polysaccharides, peptides and proteins of low molecular weight. Crystallization of an acid glycoprotein1a,b,c. J Am Chem Soc 1953; 75: 60-68.
2 Schmid K, Nimerg RB, Kimura A. et al. The carbohydrate units of human plasma alpha1-acid glycoprotein. Biochim Biophys Acta 1977; 492: 291-302.
3 De Graaf TW, Van der Stelt ME, Anbergen MG. et al. Inflammation-induced expression of sialyl Lewis X-containing glycan structures on alpha 1-acid glycoprotein (orosomucoid) in human sera. J Exp Med 1993; 177: 657-666.
4 Brinkman-van der Linden EC, van Ommen EC, van Dijk W. Glycosylation of alpha 1-acid glycoprotein in septic shock: changes in degree of branching and in expression of sialyl Lewis(x) groups. Glycoconj J 1996; 13: 27-31.
5 Ceciliani F, Pocacqua V. The acute phase protein alpha1-acid glycoprotein: a model for altered glycosylation during diseases. Curr Protein Pept Sci 2007; 08: 91-108.
6 Schmid K. Preparation and properties of an acid glycoprotein prepared from human plasma. J Am Chem Soc 1950; 72: 2816.
7 Weimer HE, Mehl JW, Winzler RJ. Studies on the mucoproteins of human plasma. V. Isolation and characterization of a homogeneous mucoprotein. J Biol Chem 1950; 185: 561-568.
8 Laine E, Couderc R, Roch-Arveiller M. et al. Modulation of human polymorphonuclear neutrophil functions by alpha 1-acid glycoprotein. Inflammation 1990; 14: 1-9.
9 Su SJ, Yang BC, Wang YS. et al. Alpha 1-acid glycoprotein-induced tumor necrosis factor-alpha secretion of human monocytes is enhanced by serum binding proteins and depends on protein tyrosine kinase activation. Immunopharmacology 1999; 41: 21-29.
10 Pos O, Oostendorp RA, van der Stelt ME. et al. Con A-nonreactive human alpha 1-acid glycoprotein (AGP) is more effective in modulation of lymphocyte proliferation than Con A-reactive AGP serum variants. Inflammation 1990; 14: 133-141.
11 Gunnarsson P, Levander L, Pahlsson P. et al. The acute-phase protein alpha 1-acid glycoprotein (AGP) induces rises in cytosolic Ca2+ in neutrophil granulocytes via sialic acid binding immunoglobulin-like lectins (siglecs). Faseb J 2007; 21: 4059-4069.
12 Sorensson J, Ohlson M, Bjornson A. et al. Orosomucoid has a cAMP-dependent effect on human endothelial cells and inhibits the action of histamine. Am J Physiol Heart Circ Physiol 2000; 278: H1725-1731.
13 Costello M, Fiedel BA, Gewurz H. Inhibition of platelet aggregation by native and desialised alpha-1 acid glycoprotein. Nature 1979; 281: 677-678.
14 Snyder S, Coodley EL. Inhibition of platelet aggregation by alpha1-acid glycoprotein. Arch Intern Med 1976; 136: 778-781.
15 Andersen P, Eika C. Inhibition of thrombin-induced platelet aggregation by crude and highly purified alpha 1-acid glycoprotein. Scand J Haematol 1980; 25: 202-204.
16 Boyum A. Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl 1968; 97: 7.
17 Varki A, Diaz S. The release and purification of sialic acids from glycoconjugates: methods to minimize the loss and migration of O-acetyl groups. Anal Biochem 1984; 137: 236-247.
18 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
19 Birkenmeier G, Kopperschlager G. Application of dye-ligant chromatography to the isolation of alpha1-proteinase inhibitor and alpha-1-acid glycoprotein. J Chromatogr 1982; 235: 237-248.
20 Azzimonti F, Atchley DH, Morrison CA. et al. One step purification of alpha(1)-acid glycoprotein from human plasma. Fractionation of its polymorphic allele products. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 33-38.
21 Rink TJ, Smith SW, Tsien RY. Cytoplasmic free Ca2+ in human platelets: Ca2+ thresholds and Ca-independent activation for shape-change and secretion. FEBS Lett 1982; 148: 21-26.
22 Amano M, Ito M, Kimura K. et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996; 271: 20246-20249.
23 Bauer M, Retzer M, Wilde JI. et al. Dichotomous regulation of myosin phosphorylation and shape change by Rho-kinase and calcium in intact human platelets. Blood 1999; 94: 1665-1672.
24 Nakai K, Suzuki Y, Kihira H. et al. Regulation of myosin phosphatase through phosphorylation of the myosin-binding subunit in platelet activation. Blood 1997; 90: 3936-3942.
25 Feng J, Ito M, Ichikawa K. et al. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999; 274: 37385-37390.
26 Watanabe Y, Ito M, Kataoka Y. et al. Protein kinase C-catalyzed phosphorylation of an inhibitory phosphoprotein of myosin phosphatase is involved in human platelet secretion. Blood 2001; 97: 3798-3805.
27 Morton LF, Peachey AR, Barnes MJ. Platelet-reactive sites in collagens type I and type III. Evidence for separate adhesion and aggregatory sites. Biochem J 1989; 258: 157-163.
28 Tandon NN, Kralisz U, Jamieson GA. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 1989; 264: 7576-7583.
29 Santoro SA, Walsh JJ, Staatz WD. et al. Distinct determinants on collagen support alpha 2 beta 1 integrin-mediated platelet adhesion and platelet activation. Cell Regul 1991; 02: 905-913.
30 Asch AS, Barnwell J, Silverstein RL. et al. Isolation of the thrombospondin membrane receptor. J Clin Invest 1987; 79: 1054-1061.
31 Kieffer N, Nurden AT, Hasitz M. et al. Identification of platelet membrane thrombospondin binding molecules using an anti-thrombospondin antibody. Biochim Biophys Acta 1988; 967: 408-415.
32 McGregor JL, Catimel B, Parmentier S. et al. Rapid purification and partial characterization of human platelet glycoprotein IIIb. Interaction with thrombospondin and its role in platelet aggregation. J Biol Chem 1989; 264: 501-506.
33 White JG, Krumwiede M. Some contributions of electron microscopy to knowledge of human platelets. Thromb Haemost 2007; 98: 69-72.
34 Blain PG, Mucklow JC, Rawlins MD. et al. Determinants of plasma alpha 1-acid glycoprotein (AAG) concentrations in health. Br J Clin Pharmacol 1985; 20: 500-502.
35 Asplund AKPersson, Palmer L, Gunnarsson P. et al. Characterisation of GEA 3175 on human platelets; comparison with S-nitroso-N-acetyl-D,L-penicillamine. Eur J Pharmacol 2004; 496: 1-9.
36 Klages B, Brandt U, Simon MI. et al. Activation of G12/G13 results in shape change and Rho/Rho-kinasemediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144: 745-754.
37 Paul BZ, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signalling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 1999; 274: 28293-28300.
38 Paul BZ, Kim S, Dangelmaier C. et al. Dynamic regulation of microtubule coils in ADP-induced platelet shape change by p160ROCK (Rho-kinase). Platelets 2003; 14: 159-169.
39 Bouaziz A, Amor NB, Woodard GE. et al. Tyrosine phosphorylation / dephosphorylation balance is involved in thrombin-evoked microtubular reorganisation in human platelets. Thromb Haemost 2007; 98: 375-384.
40 Clemetson KJ, Clemetson JM. Platelet collagen receptors. Thromb Haemost 2001; 86: 189-197.